Rare coding variants in ten genes confer substantial risk for schizophrenia

Tarjinder Singh(Broad Institute), Timothy Poterba(Broad Institute), David Curtis(Queen Mary University of London), Huda Akil(University of Michigan), Mariam Al Eissa(University College London), Jack D. Barchas(Cornell University), Nicholas Bass(University College London), Tim B. Bigdeli(SUNY Downstate Health Sciences University), Gerome Breen(King's College London), Evelyn J. Bromet(Stony Brook University), P.F. Buckley(Virginia Commonwealth University), William E. Bunney(University of California, Irvine), Jonas Bybjerg‐Grauholm(Statens Serum Institut), William Byerley(University of California, San Francisco), Sinéad B. Chapman(Broad Institute), Wei J. Chen(National Taiwan University), Claire Churchhouse(Broad Institute), Nicholas Craddock(Centre for Mental Health), Caroline Cusick(Broad Institute), Lynn E. DeLisi(Cambridge Health Alliance), Sheila Dodge(Broad Institute), Michael Escamilla(Texas Tech University), Saana Eskelinen(University of Helsinki), Ayman H. Fanous(SUNY Downstate Health Sciences University), Stephen V. Faraone(SUNY Upstate Medical University), Alessia Fiorentino(University College London), Laurent C. Francioli(Broad Institute), Stacey Gabriel(Broad Institute), Diane Gage(Broad Institute), Sarah A. Gagliano Taliun(Montreal Heart Institute), Andrea Ganna(University of Helsinki), Giulio Genovese(Broad Institute), David C. Glahn(Boston Children's Hospital), Jakob Grove(Aarhus University), Mei‐Hua Hall(Harvard University), Eija Hämäläinen(University of Helsinki), Henrike Heyne(Broad Institute), Matti Holi(University of Helsinki), David M. Hougaard(Statens Serum Institut), Daniel P. Howrigan(Broad Institute), Hailiang Huang(Broad Institute), Hai‐Gwo Hwu(National Taiwan University), René S. Kahn(James J. Peters VA Medical Center), Hyun Min Kang(University of Michigan), Konrad J. Karczewski(Broad Institute), George Kirov(Cardiff University), James A. Knowles(SUNY Downstate Health Sciences University), Francis S. Lee(Cornell University), Douglas S. Lehrer(Wright State University), Francesco Lescai(Aarhus University), Dolores Malaspina(Icahn School of Medicine at Mount Sinai), Stephen R. Marder(Icahn School of Medicine at Mount Sinai), Steven A. McCarroll(Broad Institute), Andrew M. McIntosh(University of Edinburgh), Helena Medeiros(SUNY Downstate Health Sciences University), Lili Milani(University of Tartu), Christopher P. Morley(SUNY Upstate Medical University), Derek W. Morris(Ollscoil na Gaillimhe – University of Galway), Preben Bo Mortensen(Aarhus University), R Myers(HudsonAlpha Institute for Biotechnology), Merete Nordentoft(University of Copenhagen), Niamh L. O’Brien(University College London), Ana Maria Olivares(Broad Institute), Döst Öngür(Harvard University), Willem H. Ouwehand(University of Cambridge), Duncan S. Palmer(Broad Institute), Tiina Paunio(University of Helsinki), Digby Quested(Oxford Health NHS Foundation Trust), Mark Hyman Rapaport(Emory University), Elliott Rees(Cardiff University), Brandi Rollins(University of California, Irvine), F. Kyle Satterstrom(Broad Institute), Alan F. Schatzberg(Massachusetts General Hospital), Edward M. Scolnick(Broad Institute), Laura J. Scott(University of Michigan), Sally I. Sharp(University College London), Pamela Sklar(Icahn School of Medicine at Mount Sinai), Jordan W. Smoller(Harvard University), Janet L. Sobell(University of Southern California), Matthew Solomonson(Broad Institute), Eli A. Stahl(Icahn School of Medicine at Mount Sinai), Christine Stevens(Broad Institute), Jaana Suvisaari(Finnish Institute for Health and Welfare), Grace Tiao(Broad Institute), Stanley J. Watson(University of Michigan), Nicholas A. Watts(Broad Institute), Douglas Blackwood(University of Edinburgh), Anders D. Børglum(Aarhus University), Bruce M. Cohen(Harvard University), Aiden Corvin(Trinity College Dublin), Tõnu Esko(University of Tartu), Nelson B. Freimer(Karolinska Institutet), Stephen J. Glatt(SUNY Upstate Medical University), Christina M. Hultman(Johns Hopkins University), Andrew McQuillin(University College London), Aarno Palotie(Broad Institute), Carlos N. Pato(SUNY Downstate Health Sciences University), Michele T. Pato(SUNY Downstate Health Sciences University), Ann E. Pulver(Johns Hopkins University), David St Clair(University of Aberdeen), Ming T. Tsuang(University of California San Diego), Marquis P. Vawter(University of California, Irvine), James Walters(Cardiff University), Thomas Werge(University of Copenhagen), Roel A. Ophoff(University of California, Los Angeles), Patrick F. Sullivan(University of North Carolina at Chapel Hill), Michael J. Owen(Cardiff University), Michael Boehnke(University of Michigan), Michael O‘Donovan(Cardiff University), Benjamin M. Neale(Broad Institute), Mark J. Daly(Broad Institute)
Nature
April 8, 2022
Cited by 868Open Access
Full Text

Abstract

Rare coding variation has historically provided the most direct connections between gene function and disease pathogenesis. By meta-analysing the whole exomes of 24,248 schizophrenia cases and 97,322 controls, we implicate ultra-rare coding variants (URVs) in 10 genes as conferring substantial risk for schizophrenia (odds ratios of 3–50, P < 2.14 × 10−6) and 32 genes at a false discovery rate of <5%. These genes have the greatest expression in central nervous system neurons and have diverse molecular functions that include the formation, structure and function of the synapse. The associations of the NMDA (N-methyl-d-aspartate) receptor subunit GRIN2A and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor subunit GRIA3 provide support for dysfunction of the glutamatergic system as a mechanistic hypothesis in the pathogenesis of schizophrenia. We observe an overlap of rare variant risk among schizophrenia, autism spectrum disorders1, epilepsy and severe neurodevelopmental disorders2, although different mutation types are implicated in some shared genes. Most genes described here, however, are not implicated in neurodevelopment. We demonstrate that genes prioritized from common variant analyses of schizophrenia are enriched in rare variant risk3, suggesting that common and rare genetic risk factors converge at least partially on the same underlying pathogenic biological processes. Even after excluding significantly associated genes, schizophrenia cases still carry a substantial excess of URVs, which indicates that more risk genes await discovery using this approach. Whole-exome sequencing identifies ten risk genes for schizophrenia implicated by rare protein-coding variants, a subset of which overlap with risk genes in other neurodevelopmental disorders.


Related Papers